Archive for the ‘Biotechnology’ Category

Leticia
Diaz

Text Alert: You’re having a heart attack

Wednesday, October 13th, 2010

imecIt wasn’t long ago that LifeCall, often remembered for the notorious, “I’ve fallen and I can’t get up” advertisements, was breaking into the market place with a medical alert device that, when activated, allowed individuals to call out to a device and connect to a live operator for assistance. At its core, the device provided an additional level of safety or security at home for patients and caregivers alike.

Fast forward 20 years and today’s medical alert device market is on the rise providing individuals with the ability to capture a multitude of health behavior on their mobile phones including calorie counts, physical activity and heart rate monitoring. Armed with this data from their mobile phone, patients are using the information to more closely monitor their own day-to-day health and report back to their doctor to make adjustments to diet, activity level or medication as needed. But, what if a new medical alert device sent out status updates to your physician on your body’s health in real time via your mobile phone?

(more…)

Tags: ,

 
John
Seng

Father of IVF Has His Day

Tuesday, October 5th, 2010

robert-g-edwardsNewsflash from Sweden: The father of IVF (in vitro fertilization) has won the Nobel Peace Prize for medicine.

As CNN reported, the Nobel Prize committee recognized Dr. Robert G. Edwards for developing the process that led to the birth of the first “test tube baby,” Louise Brown, in 1978.

Why do I care? Because less than 20 years later, Spectrum’s role in IVF communications began as we managed the successful media launch of the first recombinant follicle stimulating hormone (rFSH) fertility treatment available in the U.S. Spectrum led marketing communications for the rFSH brand Follistim® for Organon for years, and later guided the media launch of the Follistim Pen® injectable.

I’m proud that we have played a significant role in helping to inform caregivers and families who would like to have children understand the options and the science of IVF that Dr. Edwards pioneered.

Today, our role in supporting couples who are having difficulty becoming pregnant extends into patient advocacy through programs for RESOLVE, The National Infertility Association. We support RESOLVE in its efforts to raise public awareness about a family-building option called embryo donation. Spectrum conducted a highly successful online campaign for RESOLVE in 2009 that raised awareness among the target audiences by an average of 10 percent. In 2010, we launched a unique awareness platform on the topic of embryo donation called “Destination: Family” that offers a clearinghouse of news/information for families considering donating embryos or building a family through embryo donation.

(more…)

Tags: , ,

 
Kelly
Barrett

FDA to Make the Call: Is Genetically Engineered Salmon Safe for our Health and the Environment?

Tuesday, September 21st, 2010

Today marks the second day of an FDA hearing with scientists and experts who are presenting arguments for and against the approval of genetically engineered salmon in our food system. While the FDA appears to be leaning toward claiming genetically engineered salmon is safe, there are a number of strong opinions swimming around on both sides.

Photo credit: University of Washington

Photo credit: University of Washington

If approved, this salmon would be the first “transgenic” animal to be allowed in our food system, but it would not be the first genetically engineered food to wind up on our plate. In fact, genetically engineered plant-based foods (wheat, soybeans, canola) have been around in the U.S. for many years. Millions of people safely consume genetically modified foods every day. So what’s the big fuss about salmon?

Well, according to about 30 animal welfare, consumer, environmental and fisheries groups, including the Sierra Club and Food & Water Watch, these salmon pose both an environmental threat and a human health threat. They argue the fish could potentially escape into the ocean and wipe out wild salmon populations, as the genetically engineered salmon would be physically larger than the wild salmon, but not necessarily equipped to withstand life outside of captivity for the long term. They also warn that transgenic fish could introduce unknown allergens into our food supply. This is problematic considering fish is already in the top five for human allergies.

Aquabounty, the company who wishes to carry out the production of this genetically engineered salmon, and their supporters, argue that this salmon would feed more people and provide economic benefit to farmers by growing faster and thus allowing farmers to sell the salmon more frequently. They also argue that because these fish would be sterile, they would not serve as a threat to native populations if they escaped from their confined farms.

We have seen a number of negative and positive outcomes through the introduction of biotechnology into our food system. Perhaps this is one such case that we can all stand to benefit without encountering negative consequences later on. Let’s just hope extensive research is presented so the FDA makes the best decision for the long term.

Would you still eat salmon if this ends up getting approved, knowing that you could potentially be eating genetically engineered fish? Let us know what you think in the comments.

 
Shellie
Byrum

Device Companies Slow to Join Digital Revolution

Monday, February 1st, 2010

Medical device companies may be their own worst enemy when it comes to social media.

Since I started working in this field, I’ve noticed that device companies in general are behind in joining the digital revolution, especially when compared to other FDA-regulated companies in the pharmaceutical and biotechnology fields. In fact, a survey released in December showed that only 16 percent of FDA-regulated device companies reported using social media to connect with customers or prospects. (more…)

 
Michael
Cover

This Morning We Discovered Hope

Thursday, September 24th, 2009

This morning I woke up to news I have been waiting to hear for more than 20 years.  Researchers have finally developed a preventive vaccine against HIV that showed modest efficacy.  For every 100 people that would have become infected if they had not received the vaccine, 32 infections were prevented.  This level of efficacy (32%) is modest, and too low to proceed to license the vaccine.  However, the results are significant.  They will give a real boost to the field and provide a base on which they can improve.

While this is absolutely reason to celebrate a remarkable scientific achievement, we should note a couple of important things:

First, the vaccine was only studied with the type of HIV commonly found in Thailand.  More research will have to be done to discover whether similar results can be shown in Africa and North and South American strains.

Second, researchers also wanted to discover if the vaccine had any effect on reducing the amount of virus in the blood of volunteers who seroconverted during the trial.  Sadly, it did not have any therapeutic benefits.

Still, this is a clear victory that gives researchers, and all of us who care about ending AIDS, one thing that has been in short supply:  hope that we will be the generation that ends AIDS through the discovery of a preventive vaccine.

Tags: , ,

 
Spectrum

Stem Cell Reversal is Boon for Biotechs

Monday, March 16th, 2009

This week brought with it a lot of excitement in the scientific community, as President Obama signed an executive order to bolster human embryonic stem cell research. In 2001, President Bush signed an order prohibiting federal spending for research conducted on non-existing embryonic stem cell lines, despite the great promise these cells have for curing disease, because the cell lines would be generated by destroying human embryos.

Before reversing the Bush administration’s policy, President Obama said, “Today, with the executive order I am about to sign, we will bring the change that so many scientists and researchers, doctors and innovators, patients and loved ones have hoped for and fought for these past eight years: We will lift the ban on federal funding for promising embryonic stem cell research. We will also vigorously support scientists who pursue this research. And we will aim for America to lead the world in the discoveries it one day may yield.”

His speech mirrored the balance of cautious optimism shared by scientists and patients alike, but his measured words did not stop biotech stocks from enjoying a bump in the stock market.  California-based Geron, the company that received the first FDA approval to begin clinical studies of an embryonic stem cell therapy earlier this year, saw a 20 percent jump in stock prices. Other biotechs involved in stem cell research, such as Maryland-based Neuralstem and California-based StemCells, Inc., also saw increases.

Even small, non-traded biotechs that are dependent on the dwindling pool of venture capital are likely to see a benefit from this news. By opening up federal funding opportunities to a broad range of promising embryonic stem cell research, small biotechs working with embryonic stem cells can seek alternative sources of funding, such as university collaborations and federal grants, just as the economic downturn is drying up VC spending.

Juhi Kunde, Science Writer & Senior Account Executive

Tags: ,